FDA panel endorses first-of-a-kind cancer blood test from Grail

A federal advisory panel recommended FDA approval of Grail's Galleri blood test, which detects signals of multiple cancers from a single blood draw in people aged 50 and older, potentially expanding cancer screening options though questions about test accuracy and clinical benefits remain.

This Wire brief sits within Fusion42's coverage of Health, and 10 sources have reported it between 21 Sep 2026 and 3 Oct 2026.